ADORA3 and psoriasis: For example, selective and potent A3 adenosine receptor agonists are currently undergoing clinical trials for psoriasis (Phase III; Piclidenoson, CanFite BioPharma) and liver diseases (Phase II; Namodenoson, CanFite BioPharma).